Table 1.
Pathogen | Clinical settings and resistance headlines |
---|---|
Enterococcus faecium | Bloodstream, surgical site and urinary tract infections (UTI) |
Staphylococcus Aureus | Skin and wound infections, pneumonia, bloodstream infections |
Klebsiella pneumoniae | Bloodstream, UTI, catheter-related infections, ventilator associated pneumonia (VAP). Major issues with resistance to carbapenems; notably through emergence of “Klebsiella pneumoniae carbapenemase” (KPC) producing isolates |
Acinetobacter baumannii | Bloodstream infections, wounds, VAP At least 63% of Acinetobacter isolates are resistant to >3 classes of front-line antibiotic. |
Pseudomonas Aeruginosa | Bloodstream, urinary tract and surgical site infections, pneumonia (cystic fibrosis), VAP ~13% of Pseudomonas isolates are resistant to >3 classes of front-line antibiotic. |
Enterobacter sp | Bloodstream, UTI, catheter-related infections, |
Escherichia coli | Bloodstream, urinary tract and surgical site infections, pneumonia (cystic fibrosis) |
Burkholderia cepacia / cenocepacia | Cystic fibrosis, VAP Intrinsically drug resistant and becoming a major problem in conjunction with other pathogens in the lung |
Stenotrophomonas maltophilia | Various Intrinsically drug resistant and associated with infections in a number of hospital settings. |